MedTrace Logo

GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake

NCT03526289 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2018-12-05

No results posted yet for this study

Summary

The primary aim of the study is to evaluate how GIP receptor activation influence food intake and mechanisms regulating food intake in obese individuals with type 2 diabetes that are in steady treatment with metformin and a GLP-1 receptor agonist.

Conditions

Interventions

BIOLOGICAL

GIP1-42 infusion

5-hour GIP1-42 infusion (time point 0-300 minutes)

OTHER

Saline

5-hour infusion of saline (placebo) (time point 0-300 minutes)

Sponsors & Collaborators

  • Zealand Pharma

    collaborator INDUSTRY

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-08
Primary Completion
2018-10-24
Completion
2018-10-24

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526289 on ClinicalTrials.gov